GuidelineCanadian journal of gastroenterology & hepatology
An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver.
Guideline in Canadian journal of gastroenterology & hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- DAA treatment for HCV reduce risk of hepatocellular carcinoma: a 10-years follow-up study based on Chinese patients with hepatitis C.Scientific reports · 2024Article
- Expanding access to healthcare for people who use drugs and sex workers: hepatitis C elimination implications from a qualitative study of healthcare experiences in British Columbia, Canada.Harm reduction journal · 2024Article
- RdRp (RNA-dependent RNA polymerase): A key target providing anti-virals for the management of various viral diseases.Journal of molecular structure · 2022Review
- Discovery of Potential Therapeutic Drugs for COVID-19 Through Logistic Matrix Factorization With Kernel Diffusion.Frontiers in microbiology · 2022Article
- Plant-Based Phytochemical Screening by Targeting Main Protease of SARS-CoV-2 to Design Effective Potent Inhibitors.Biology · 2021Article
- Synthesis of α-substituted 2-(1Tetrahedron letters · 2021Article
- "I want to get better, but…": identifying the perceptions and experiences of people who inject drugs with respect to evolving hepatitis C virus treatments.International journal for equity in health · 2021Article
- Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma.Frontiers in oncology · 2021Review
- Prescribing trends in direct-acting antivirals for the treatment of hepatitis C in Ontario, Canada.Canadian liver journal · 2021Article
- Characterizing risk behaviour and reinfection rates for successful programs to engage core transmitters in HCV elimination (C-RESPECT).Canadian liver journal · 2021Article
- NASH in HIV.Current HIV/AIDS reports · 2020Review
- Social values for health technology assessment in Canada: a scoping review of hepatitis C screening, diagnosis and treatment.BMC public health · 2020Article
- CSF3 Is a Potential Drug Target for the Treatment of COVID-19.Frontiers in physiology · 2020Article
- Real-world health care utilization in treatment of HCV: Results from the Canadian SIMPLE observational trial.Canadian liver journal · 2019Article
- Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2018Observational
- Clinical Pharmacokinetics and Drug-Drug Interactions of Elbasvir/Grazoprevir.European journal of drug metabolism and pharmacokinetics · 2018Article
- The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2018Article
- Hepatitis C virus core protein reduces CD8Immunology · 2018Article
- Ribavirin-induced anaemia reduced tacrolimus level in a hepatitis C patient receiving haemodialysis.BMJ case reports · 2018Article
- Hepatitis C cascade of care among people who inject drugs in Vancouver, Canada.Substance abuse · 2018Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic hepatitis C remains a significant medical and economic burden in Canada, affecting nearly 1% of the population. Since the last Canadian consensus conference on the management of chronic hepatitis C, major advances have occurred that warrant a review of recommended management approaches for these patients. Specifically, direct-acting antiviral agents with dramatically improved rates of virological clearance compared with standard therapy have been developed and interferon-free, all-oral antiviral regimens have been approved. In light of this new evidence, an update to the 2012 Canadian Association for the Study of the Liver consensus guidelines on the management of hepatitis C was produced. The present document reviews the epidemiology of hepatitis C in Canada, preferred diagnostic testing approaches and recommendations for the treatment of chronically infected patients with the newly approved antiviral agents, including those who have previously failed peginterferon and ribavirin-based therapy. In addition, recommendations are made regarding approaches to reducing the burden of hepatitis C in Canada.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.